Sue D. Pedersen

11.3k total citations · 7 hit papers
49 papers, 4.2k citations indexed

About

Sue D. Pedersen is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Molecular Biology. According to data from OpenAlex, Sue D. Pedersen has authored 49 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 24 papers in Pharmacology and 18 papers in Molecular Biology. Recurrent topics in Sue D. Pedersen's work include Diabetes Treatment and Management (28 papers), Pharmacology and Obesity Treatment (24 papers) and Metabolism, Diabetes, and Cancer (18 papers). Sue D. Pedersen is often cited by papers focused on Diabetes Treatment and Management (28 papers), Pharmacology and Obesity Treatment (24 papers) and Metabolism, Diabetes, and Cancer (18 papers). Sue D. Pedersen collaborates with scholars based in Canada, Denmark and United States. Sue D. Pedersen's co-authors include Ildiko Lingvay, Ofri Mosenzon, Ole Kleist Jeppesen, Andreas L. Birkenfeld, Melanie J. Davies, Sean Wharton, Mette S. Thomsen, Cees J. Tack, Freddy G. Eliaschewitz and Mansoor Husain and has published in prestigious journals such as New England Journal of Medicine, The Lancet and American Journal of Clinical Nutrition.

In The Last Decade

Sue D. Pedersen

47 papers receiving 4.1k citations

Hit Papers

Oral Semaglutide and Cardiovascular Outcomes in Patients ... 2018 2026 2020 2023 2019 2021 2018 2023 2021 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    2019 1.2k citations Andreas L. Birkenfeld, Ole Kleist Jeppesen et al. profile →
  2. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
    2021 806 citations Melanie J. Davies, Louise Færch et al. The Lancet profile →
  3. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
    2018 574 citations Patrick M. O’Neil, Andreas L. Birkenfeld et al. The Lancet profile →
  4. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
    2023 193 citations Juan P. Frías, Srikanth Deenadayalan et al. The Lancet profile →
  5. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
    2021 162 citations David C.W. Lau, Lars Erichsen et al. The Lancet profile →
  6. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
    2024 73 citations Barbara McGowan, Sue D. Pedersen et al. profile →
  7. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
    2025 19 citations Melanie J. Davies, Carel W. le Roux et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sue D. Pedersen Canada 21 3.0k 1.5k 1.3k 1.0k 980 49 4.2k
Salvatore Calanna Denmark 20 2.6k 0.9× 1.3k 0.9× 1.1k 0.8× 1.0k 1.0× 1.0k 1.1× 27 4.0k
Christine B. Jensen Denmark 22 2.5k 0.9× 1.8k 1.2× 1.2k 0.9× 1.5k 1.5× 898 0.9× 26 4.2k
Domenica Rubino United States 23 2.3k 0.8× 1.6k 1.1× 849 0.6× 989 1.0× 567 0.6× 60 3.4k
Paula M. Hale United States 19 3.4k 1.2× 1.4k 1.0× 1.6k 1.2× 708 0.7× 1.2k 1.2× 43 4.2k
Niels Zeuthen Denmark 6 1.6k 0.6× 1.1k 0.8× 655 0.5× 811 0.8× 626 0.6× 17 2.7k
Marie Thi Dao Tran Denmark 6 1.5k 0.5× 1.0k 0.7× 599 0.5× 792 0.8× 597 0.6× 11 2.6k
Nadia N. Ahmad United States 12 1.5k 0.5× 1.1k 0.7× 490 0.4× 1.0k 1.0× 621 0.6× 26 2.7k
Ole Kleist Jeppesen Denmark 10 2.2k 0.7× 931 0.6× 1.0k 0.8× 528 0.5× 666 0.7× 20 2.9k
Adam Stefański United States 18 1.5k 0.5× 932 0.6× 554 0.4× 883 0.9× 561 0.6× 64 2.9k
Mathijs C. Bunck United States 10 1.6k 0.5× 1.0k 0.7× 458 0.3× 968 0.9× 578 0.6× 21 2.7k

Countries citing papers authored by Sue D. Pedersen

Since Specialization
Citations

This map shows the geographic impact of Sue D. Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sue D. Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sue D. Pedersen more than expected).

Fields of papers citing papers by Sue D. Pedersen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sue D. Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sue D. Pedersen. The network helps show where Sue D. Pedersen may publish in the future.

Co-authorship network of co-authors of Sue D. Pedersen

This figure shows the co-authorship network connecting the top 25 collaborators of Sue D. Pedersen. A scholar is included among the top collaborators of Sue D. Pedersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sue D. Pedersen. Sue D. Pedersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wharton, Sean, Carel W. le Roux, Mikhail Kosiborod, et al.. (2024). Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity. 33(1). 67–77. 11 indexed citations
2.
Ritz, Patrick, A. Sharma, Jakob B. Bjorner, et al.. (2023). Association entre une meilleure perte de poids et une meilleure amélioration de la fonction physique. Nutrition Clinique et Métabolisme. 37(2). e87–e87. 1 indexed citations
3.
Goldenberg, Ronald, Jeremy Gilbert, Priya Manjoo, et al.. (2023). Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists. Obesity Reviews. 25(3). e13663–e13663. 16 indexed citations
4.
5.
Pedersen, Sue D., Francesco Giorgino, Guillermo E. Umpierrez, et al.. (2023). Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme. Diabetes Obesity and Metabolism. 25(9). 2553–2560. 11 indexed citations
6.
Rubino, Domenica, Sue D. Pedersen, Lisa Connery, et al.. (2023). TOLERABILITY AND WEIGHT REDUCTION OF TIRZEPATIDE IN ADULTS WITH OBESITY OR OVERWEIGHT. Canadian Journal of Diabetes. 47(7). S136–S136. 1 indexed citations
7.
Frías, Juan P., Srikanth Deenadayalan, Lars Erichsen, et al.. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet. 402(10403). 720–730. 193 indexed citations breakdown →
8.
Aroda, Vanita R., Jens Aberle, Erik Christiansen, et al.. (2023). Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. The Lancet. 402(10403). 693–704. 67 indexed citations
9.
Lau, David C.W., Lars Erichsen, Ann Marie Ocampo Francisco, et al.. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 398(10317). 2160–2172. 162 indexed citations breakdown →
10.
11.
Davies, Melanie J., Louise Færch, Ole Kleist Jeppesen, et al.. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 397(10278). 971–984. 806 indexed citations breakdown →
12.
Garvey, W. Timothy, Andreas L. Birkenfeld, Dror Dicker, et al.. (2020). Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 43(5). 1085–1093. 139 indexed citations
13.
O’Neil, Patrick M., Andreas L. Birkenfeld, Barbara McGowan, et al.. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 392(10148). 637–649. 574 indexed citations breakdown →
14.
Nielsen, Mette S., et al.. (2016). Efficacy of a liquid low-energy formula diet in achieving preoperative target weight loss before bariatric surgery. Journal of Nutritional Science. 5. e22–e22. 24 indexed citations
15.
Schmidt, Julie Berg, Sue D. Pedersen, Nikolaj Ture Gregersen, et al.. (2015). Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial. International Journal of Obesity. 40(2). 281–290. 64 indexed citations
16.
Pedersen, Sue D.. (2013). Metabolic complications of obesity. Best Practice & Research Clinical Endocrinology & Metabolism. 27(2). 179–193. 58 indexed citations
17.
18.
Chaput, Jean‐Philippe, Jo‐Anne Gilbert, Nikolaj Ture Gregersen, Sue D. Pedersen, & Anders Sjödin. (2010). Comparison of 150-mm versus 100-mm visual analogue scales in free living adult subjects. Appetite. 54(3). 583–586. 26 indexed citations
19.
Pedersen, Sue D.. (2007). Portion Control Plate for Weight Loss in Obese Patients With Type 2 Diabetes Mellitus. Archives of Internal Medicine. 167(12). 1277–1277. 74 indexed citations
20.
Pedersen, Sue D., Hannah Parsons, & Deborah Dewey. (2004). Stress levels experienced by the parents of enterally fed children. Child Care Health and Development. 30(5). 507–513. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Salvatore Calanna Breakdown of academic impact, for papers by Christine B. Jensen Breakdown of academic impact, for papers by Domenica Rubino Breakdown of academic impact, for papers by Paula M. Hale Breakdown of academic impact, for papers by Niels Zeuthen Breakdown of academic impact, for papers by Marie Thi Dao Tran Breakdown of academic impact, for papers by Nadia N. Ahmad Breakdown of academic impact, for papers by Ole Kleist Jeppesen Breakdown of academic impact, for papers by Adam Stefański Breakdown of academic impact, for papers by Mathijs C. Bunck
Rankless by CCL
2026